Jefferies Maintains Bullish Stance on Infinity Pharmaceutical (INFI) Following ASCO Update

Jefferies analyst Eun K. Yang reiterated a Buy rating and $18 price target on Infinity Pharmaceutical (NASDAQ: INFI) following the company's ASCO update.

Yang commented, "In 1st-line CLL, as a single agent, duvelisib data shows comparable ORR as ibrutinib. Key to capturing significant market share, if approved, is potential efficacy/utility in combination therapies (e.g., with ABT-199, anti-CD20 mAb). INFI and partner ABBV are to begin duvelisib/ABT-199 combination studies in hematologic malignancies in 2015."

For an analyst ratings summary and ratings history on Infinity Pharmaceutical click here. For more ratings news on Infinity Pharmaceutical click here.

Shares of Infinity Pharmaceutical closed at $12.23 yesterday.

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)